BriaCell Reports Quadrupled PFS in Patient with Metastatic Breast Cancer

July 18, 2024

DENVER, Colo., Jul 18, 2024 (247marketnews.com)- BriaCell Therapeutics Corp. (Nasdaq:BCTX) reported substantially higher Progression Free Survival (PFS) for its top responder patient in the Phase 2 study, who remains alive and continues to receive BriaCell’s Bria-IMT regimen in combination with an immune checkpoint inhibitor in metastatic breast cancer.

Dr. William V. Williams, BriaCell’s President and CEO, commented, “We are extremely pleased with the unprecedented survival benefit in this very-difficult-to-treat patient.

“This data represents a step forward in our efforts to build on our knowledge and successes to transform cancer care for patients. We expect to replicate this positive data in our ongoing Phase 3 study and bring relief to cancer patients whose medical needs remain unmet.”

Dr. Giuseppe Del Priore, BriaCell’s Chief Medical Officer, added, “Despite recent advances in cancer therapy, metastatic breast cancer remains an unmet medical need, as current treatments are limited by poor survival and harsh side effects.

“The Bria-IMT™ regimen produced a much longer than expected survival benefit in addition to its favorable safety and tolerability in this patient suggesting its potential as a therapeutic option for these cancer patients.”

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (BCTX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.